Nagahama T, Maruyama M, Toukairin Y, Baba H, Yoshida T, Kure N, Ebuchi M, Yamada F, Ikeda T
Dept. of Surgery, Tokyo Metropolitan Ohkubo Hospital.
Gan To Kagaku Ryoho. 2000 Oct;27(12):1920-3.
The results and problems of hepatic artery infusion therapy (HAI) for gastric carcinoma with synchronous liver metastasis were evaluated. The response rate of HAI with CDDP and 5-FU for metastatic liver tumor was 55% (1 CR + 5 PR/11). The median survival time for responders was 16.5 months, which was statistically longer than that of non-responders at only 5.5 months. Histologically, most responder cases were with AFP producing tumors and NSE positive tumors without distant lymph node involvement. Non-responder cases developed marked distant lymph node involvement besides the liver metastasis. Most of responder patients died of lymph node recurrence or distant metastasis other than liver tumor. It may be concluded that additional therapy to HAI is needed to improve the prognosis of gastric cancer patients with multiple liver metastases.
对同步肝转移的胃癌患者进行肝动脉灌注治疗(HAI)的结果及问题进行了评估。HAI联合顺铂(CDDP)和5-氟尿嘧啶(5-FU)对转移性肝肿瘤的缓解率为55%(1例完全缓解+5例部分缓解/11例)。缓解者的中位生存时间为16.5个月,在统计学上显著长于未缓解者,后者仅为5.5个月。组织学上,大多数缓解病例为产生甲胎蛋白(AFP)的肿瘤和神经元特异性烯醇化酶(NSE)阳性肿瘤,且无远处淋巴结受累。未缓解病例除肝转移外还出现明显的远处淋巴结受累。大多数缓解患者死于淋巴结复发或肝肿瘤以外的远处转移。可以得出结论,需要对HAI进行额外治疗以改善多发肝转移胃癌患者的预后。